Tag Archives: Novartis

Novartis slaps $2M-plus pricetag on newly approved gene therapy Zolgensma—and cost watchdogs approve

Industry watchers have been speculating for months about just how high Novartis would price gene therapy Zolgensma on approval—and just how payers would cover it. And with the FDA’s green light, they now have an answer. The Swiss drugmaker will roll out the drug, a one-time treatment for pediatric patients less than 2 years of… Read More »

Novartis trial win lifts profile of new breast cancer drug

ZURICH (Reuters) – Novartis’s efforts to tackle an elusive gene mutation behind tough-to-treat breast cancer were rewarded on Thursday, as the Swiss drugmaker said one of its investigational medicines slowed disease progression. FILE PHOTO: Swiss drugmaker Novartis’ logo is seen at the company’s plant in the northern Swiss town of Stein, Switzerland October 23, 2017.… Read More »